| PRECLINICAL | evidence | Nutrition-First Support for GLP-1 and Dual Incretin Therapy in Obesity: A Practical Framework for Dietary Management, Symptom Tolerability, and Long-Term Weight Maintenance. | Semaglutide | Weight & fat loss | 2026-05-29 |
| PRECLINICAL | evidence | Insights into semaglutide cardiovascular research: Mechanisms, trials, and frontiers. | Semaglutide | — | 2026-05-28 |
| PRECLINICAL | evidence | After the Prescription: The Clinical Support Gap in Telehealth-Based GLP-1 Care. | Semaglutide | Weight & fat loss | 2026-05-28 |
| PRECLINICAL | evidence | Differential Biliary Adverse Event Signals Among Glp-1 Receptor Agonists: A FAERS Disproportionality Analysis. | Semaglutide | — | 2026-05-28 |
| PRECLINICAL | evidence | Evaluation of the safety profile of glucagon-like peptide-1 receptor agonists: a focus on thyroid cancer-related adverse events by using the European pharmacovigilance database. | Semaglutide | — | 2026-05-28 |
| PRECLINICAL | evidence | Safety, tolerability and efficacy of GLP-1 receptor agonists (GLP-1 RA) in the management of post-liver transplant weight gain: A multicenter, observational study. | Semaglutide | — | 2026-05-28 |
| PRECLINICAL | evidence | Shrinking appetites: Will GLP-1 adoption in high-income countries accelerate Big Food's push into low- and middle-income countries? | Ozempic | — | 2026-05-28 |
| PRECLINICAL | evidence | Lean Mass and Musculoskeletal Preservation in GLP-1-Based Obesity Treatment: Nutrition, Exercise, Supplementation, and Monitoring Strategies. | Semaglutide | — | 2026-05-27 |
| PRECLINICAL | evidence | An Ionic Liquid-Based Enteric Formulation for Enhanced Oral Delivery of Semaglutide in Type 2 Diabetes Mellitus. | Rybelsus | Glycemic control | 2026-05-27 |
| PRECLINICAL | evidence | Glucagon-Like Peptide-1 Receptor Agonists Inhibit the Initiation of Toxic Amyloid-beta42 Aggregation. | Semaglutide | — | 2026-05-27 |
| PRECLINICAL | evidence | Semaglutide and risk of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) in type 2 diabetes mellitus: A systematic review and meta-analysis. | Semaglutide | — | 2026-05-27 |
| PRECLINICAL | evidence | Inter-organ communication shapes human metabolic tissue states and resolves anti-diabetic drug response modes in a six-tissue microphysiological system. | Semaglutide | — | 2026-05-27 |
| PRECLINICAL | evidence | Redox-Driven Blood-Nerve Barrier Dysfunction in Diabetic Peripheral Neuropathy: Mechanisms and Therapeutic Opportunities. | Semaglutide | — | 2026-05-26 |
| PRECLINICAL | evidence | Glucagon-like Peptide-1 Receptor Agonists and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy: Systematic Review and Meta-Analysis. | Semaglutide | Glycemic control | 2026-05-26 |
| PRECLINICAL | evidence | Weight Loss, Adverse Effects With GLP-1 Medications May Be Influenced by Genetics. | Semaglutide | — | 2026-05-26 |
| PRECLINICAL | evidence | Methyl Proton Spin Relaxation (R(2)/R(1)) Enables Sensitive Detection of pH-Dependent Oligomerization in GLP-1 Analogs. | Semaglutide | — | 2026-05-26 |
| PRECLINICAL | evidence | Targeting mTOR with vistusertib attenuates metabolic steatohepatitis and prevents HCC development. | Semaglutide | Liver health | 2026-05-26 |
| PRECLINICAL | evidence | GLP-1 receptor agonist therapy before bariatric surgery: Effects on weight loss and body composition in clinical practice. | Semaglutide | — | 2026-05-26 |
| PRECLINICAL | evidence | The "microdosing" dilemma: Balancing patient anecdotes with clinical safety amid GLP-1 compounding restrictions. | Semaglutide | — | 2026-05-26 |
| PRECLINICAL | evidence | Use of GLP-1 Receptor Agonists is Associated with an Increased Rate of Upper Eyelid Blepharoplasty. | Ozempic | — | 2026-05-26 |
| PRECLINICAL | evidence | Evaluation of the Efficacy of Semaglutide Dose Escalation in Reducing HbA1c Levels and Insulin Dose in Type 2 Diabetes Patients: Real-World Semaglutide Data from Turkiye, SEMA-TR Study. | Semaglutide | — | 2026-05-26 |
| PRECLINICAL | evidence | The safety and efficacy of semaglutide in people with schizophrenia spectrum disorders: systematic review and meta-analysis of randomised controlled trials. | Semaglutide | — | 2026-05-25 |
| PRECLINICAL | evidence | Glucagon-Like Peptide 1 Receptor Agonists are Associated With Reduced Risk of Hepatic Encephalopathy in Cirrhosis. | Semaglutide | — | 2026-05-25 |
| PRECLINICAL | evidence | To Reenvision and Redefine: Considering the Role of Lifestyle Interventions in the New Era of Second-Generation Obesity Management Medications. | Semaglutide | Weight & fat loss | 2026-05-25 |
| PRECLINICAL | evidence | Phenome-wide analysis of downstream health outcomes following second-line antidiabetic agent prescriptions in All of Us. | Semaglutide | Glycemic control | 2026-05-25 |
| PRECLINICAL | evidence | Orforglipron (Foundayo) - a second oral GLP-1 receptor agonist for weight loss. | Wegovy | — | 2026-05-25 |
| PRECLINICAL | evidence | Semaglutide targets the Isg15-FUNDC1 axis: suppressing IFN-beta overactivation and attenuating blood-brain barrier injury in diabetic intracerebral hemorrhage. | Semaglutide | — | 2026-05-25 |
| PRECLINICAL | evidence | Effects of semaglutide on mortality, cardiovascular, and kidney outcomes across the cardio-kidney-metabolic continuum: a systematic review and meta-analysis. | Semaglutide | — | 2026-05-25 |
| PRECLINICAL | evidence | Lifestyle First and Lifestyle Always, Does Not Mean Lifestyle Only: Reimagining Cardiometabolic Care in the Era of GLP-1 Receptor Agonists. | Semaglutide | — | 2026-05-25 |
| PRECLINICAL | evidence | Benefits of Incretin Therapy on Ovarian Function: A Scientific Literature Review. | Semaglutide | Weight & fat loss | 2026-05-25 |
| PRECLINICAL | evidence | Benchmarking size-exclusion chromatography columns for the analysis of therapeutic peptides and model oligonucleotides. | Semaglutide | — | 2026-05-24 |
| PRECLINICAL | evidence | Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review. | Semaglutide | Glycemic control | 2026-05-22 |
| PRECLINICAL | evidence | Projected reduction in major adverse cardiovascular events among high-risk U.S. adults with type 2 diabetes eligible for oral semaglutide: a SOUL trial-based analysis using NHANES (1988-2018) cycles. | Semaglutide | — | 2026-05-22 |
| PRECLINICAL | evidence | GLP-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease: mechanistic networks and translational implications: a review. | Semaglutide | — | 2026-05-22 |
| PRECLINICAL | evidence | Glycaemic changes during early semaglutide treatment: a case of pancreatic adenocarcinoma. | Semaglutide | — | 2026-05-22 |
| PRECLINICAL | evidence | Impact of GLP-1 Receptor Agonists on Chronic Low Back Pain in Patients with Obesity: A Prospective Pilot Cohort Study. | Semaglutide | — | 2026-05-22 |
| PRECLINICAL | evidence | GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists in Children and Adolescents with Obesity: Clinical Outcomes and the Impact of Nutritional and Behavioral Co-Interventions-A Systematic Review. | Semaglutide | Weight & fat loss | 2026-05-22 |
| PRECLINICAL | evidence | Retrospective Comparative Study of Oral Versus Subcutaneous Semaglutide in Patients with Type 2 Diabetes Mellitus. | Semaglutide | Glycemic control | 2026-05-22 |
| PRECLINICAL | evidence | Effect of oral semaglutide on cardiometabolic risk factors in overweight and obese individuals with or without diabetes: a systematic review and meta-analysis. | Semaglutide | — | 2026-05-21 |
| PRECLINICAL | evidence | The Paradox and Future of GLP-1/GIP Combination Therapies: Efficacy and Mechanisms. | Semaglutide | — | 2026-05-21 |
| PRECLINICAL | evidence | Association of Glucagon-like Peptide-1 Receptor Agonist Use with Stroke and Mortality Outcomes in Asymptomatic Intracranial Atherosclerotic Disease: Propensity Score-Matched Real-World Analysis. | Semaglutide | — | 2026-05-21 |
| PRECLINICAL | evidence | Lycopene Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease via PINK1/Parkin-Mediated Mitophagy Activation and Apoptosis Attenuation. | Semaglutide | — | 2026-05-21 |
| PRECLINICAL | evidence | Glucagon-like peptide-1 receptor agonist, semaglutide, attenuates intravenous self-administration of fentanyl in female rats. | Semaglutide | — | 2026-05-21 |
| PRECLINICAL | evidence | Repurposing semaglutide as an adjunctive treatment for cocaine use disorder: protocol for a randomised controlled trial. | Semaglutide | Cognition & memory · n = 75 | 2026-05-20 |
| PRECLINICAL | evidence | Effects of GLP-1 Receptor Agonists on Skin Quality: A Comprehensive Literature Review. | Ozempic | — | 2026-05-20 |
| PRECLINICAL | evidence | [Glucagon-like peptide-1 agonists and heart failure]. | Semaglutide | Glycemic control | 2026-05-20 |
| PRECLINICAL | evidence | Oral Semaglutide Sustains Long-Term CVD Risk Factor Reductions. | Semaglutide | — | 2026-05-19 |
| PRECLINICAL | evidence | Diabetes Mellitus and Stroke: Pathophysiological Connections and Therapeutic Potential of GLP-1 and GLP-1/GIP Receptor Agonists. | Semaglutide | — | 2026-05-19 |
| PRECLINICAL | evidence | Ozempic generic approved in Canada after Novo Nordisk doesn't pay $250 government fee. | Ozempic | — | 2026-05-19 |
| PRECLINICAL | evidence | Pharmacovigilance Assessment of Thrombotic Adverse Events Linked to GLP-1 Receptor Agonists: Analysis of FAERS Reports from 2020-2025. | Semaglutide | — | 2026-05-19 |